{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:02:12Z","timestamp":1791943332297,"version":"4.3.4"},"publisher-location":"Cham","reference-count":48,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031271557","type":"print"},{"value":"9783031271564","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-3-031-27156-4_6","type":"book-chapter","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T06:02:03Z","timestamp":1686549723000},"page":"91-104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hormonal Therapies in Cancers"],"prefix":"10.1007","author":[{"given":"Muhammad Rizwan","family":"Tariq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinawar Waseem","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sehar Anam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Yamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waseem","family":"Safdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Naveed","family":"Sheas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"6_CR1","doi-asserted-by":"crossref","unstructured":"Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNCI J Natl Cancer Inst 90(18):1371\u20131388","DOI":"10.1093\/jnci\/90.18.1371"},{"issue":"18","key":"6_CR2","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/jnci\/91.18.1541","volume":"91","author":"JP Costantino","year":"1999","unstructured":"Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91(18):1541\u20131548","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"6_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0959-8049(99)00304-4","volume":"36","author":"C Thomssen","year":"2000","unstructured":"Thomssen C, J\u00e4nicke F (2000) Do we need better prognostic factors in node-negative breast cancer? Pro. Eur J Cancer 36(3):293\u2013298","journal-title":"Eur J Cancer"},{"key":"6_CR4","first-page":"151","volume":"50","author":"JI MacGregor","year":"1998","unstructured":"MacGregor JI, Jordan VC (1998) Basic guide to the mechanisms of antiestrogen action. Pharm Rev 50:151\u2013196","journal-title":"Pharm Rev"},{"key":"6_CR5","doi-asserted-by":"crossref","unstructured":"Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Treleaven JG (1989) A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60(1):126\u2013131","DOI":"10.1038\/bjc.1989.235"},{"issue":"3","key":"6_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0020-7292(95)02387-R","volume":"49","author":"VJ Assikis","year":"1995","unstructured":"Assikis VJ, Jordan VC (1995) Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynecol Obstet 49(3):241\u2013257","journal-title":"Int J Gynecol Obstet"},{"key":"6_CR7","doi-asserted-by":"crossref","unstructured":"Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, Ford L (1999) Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91(19):1654\u20131662","DOI":"10.1093\/jnci\/91.19.1654"},{"issue":"9233","key":"6_CR8","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(00)02677-5","volume":"356","author":"L Bergman","year":"2000","unstructured":"Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE (2000) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 356(9233):881\u2013887","journal-title":"Lancet"},{"key":"6_CR9","doi-asserted-by":"crossref","unstructured":"Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337(23):1641\u20131647","DOI":"10.1056\/NEJM199712043372301"},{"issue":"3","key":"6_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0368-2242(59)80037-3","volume":"10","author":"R Paterson","year":"1959","unstructured":"Paterson R, Russell MH (1959) Clinical trials in malignant disease: Ppart II\u2014breast cancer: value of irradiation of the ovaries. J Fac Radiol 10(3):130\u2013133","journal-title":"J Fac Radiol"},{"issue":"5","key":"6_CR11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/oxfordjournals.annonc.a057952","volume":"2","author":"R Nissen-Meyer","year":"1991","unstructured":"Nissen-Meyer R (1991) Primary breast cancer: the effect of primary ovarian irradiation. Ann Oncol 2(5):343\u2013346","journal-title":"Ann Oncol"},{"issue":"9036","key":"6_CR12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/S0140-6736(96)05023-4","volume":"348","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1996","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (1996) Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348(9036):1189\u20131196","journal-title":"Lancet"},{"issue":"6","key":"6_CR13","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/1097-0142(196912)24:6<1350::AID-CNCR2820240651>3.0.CO;2-A","volume":"24","author":"JJ Stein","year":"1969","unstructured":"Stein JJ (1969) Surgical or irradiation castration for patients with advanced breast cancer. Cancer 24(6):1350\u20131354","journal-title":"Cancer"},{"issue":"5","key":"6_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/bjc.1986.106","volume":"53","author":"MR Williams","year":"1986","unstructured":"Williams MR, Walker KJ, Turkes A, Blamey RW, Nicholson RI (1986) The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53(5):629\u2013636","journal-title":"Br J Cancer"},{"key":"6_CR15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/0959-8049(92)90120-Q","volume":"28A","author":"RW Blamey","year":"1992","unstructured":"Blamey RW, Jonat W, Kaufmann M et al (1992) Goserelin depot in the treatment of pre-menopausal advanced breast cancer. Eur J Cancer 28A:810\u2013814","journal-title":"Eur J Cancer"},{"key":"6_CR16","doi-asserted-by":"crossref","unstructured":"Furr BJA (1989) Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex. Horm Res Paediatr 32(Suppl. 1):86\u201392","DOI":"10.1159\/000181318"},{"issue":"6","key":"6_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/0960-0760(90)90455-T","volume":"37","author":"RI Nicholson","year":"1990","unstructured":"Nicholson RI, Walker KJ, McClelland RA, Dixon A, Robertson JFR, Blamey RW (1990) Zoladex\u00ae plus tamoxifen versus zoladex\u00ae alone in pre-and peri-menopausal metastatic breast cancer. J Steroid Biochem Mol Biol 37(6):989\u2013995","journal-title":"J Steroid Biochem Mol Biol"},{"key":"6_CR18","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"EBC Trialists","year":"1998","unstructured":"Trialists EBC (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists\u2019 Collaborative Group. Lancet 351:1451\u20131467","journal-title":"Lancet"},{"issue":"9132","key":"6_CR19","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","volume":"352","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352(9132):930\u2013942","journal-title":"Lancet"},{"key":"6_CR20","doi-asserted-by":"crossref","unstructured":"Seidman H, Mushinski MH, Gelb S, Silverberg E (1985) Probabilities of eventually developing or dying of cancer\u2014United States, 1985. CA Cancer J Clin 35(1):36\u201356","DOI":"10.3322\/canjclin.35.1.36"},{"key":"6_CR21","doi-asserted-by":"crossref","unstructured":"Daling JR, Malone KE, Voigt LF, White E, Weiss NS (1994) Risk of breast cancer among young women: relationship to induced abortion. JNCI J Natl Cancer Inst 86(21):1584\u20131592","DOI":"10.1093\/jnci\/86.21.1584"},{"issue":"4","key":"6_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1001\/jama.1996.03530280035033","volume":"275","author":"PA Newcomb","year":"1996","unstructured":"Newcomb PA, Storer BE, Longnecker MP, Mittendorf R, Greenberg ER, Willett WC (1996) Pregnancy termination in relation to risk of breast cancer. JAMA 275(4):283\u2013287","journal-title":"JAMA"},{"key":"6_CR23","doi-asserted-by":"crossref","unstructured":"Seidman H, Stellman SD, Mushinski MH (1982) A different perspective on breast cancer risk factors: some implications of the nonattributable risk. CA Cancer J Clin 32(5):301\u2013313","DOI":"10.3322\/canjclin.32.5.301"},{"issue":"9","key":"6_CR24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/0024-3205(83)90935-9","volume":"32","author":"LJ Black","year":"1983","unstructured":"Black LJ, Jones CD, Falcone JF (1983) Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 32(9):1031\u20131036","journal-title":"Life Sci"},{"issue":"17","key":"6_CR25","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/0024-3205(80)90049-1","volume":"26","author":"LJ Black","year":"1980","unstructured":"Black LJ, Goode RL (1980) Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. Life Sci 26(17):1453\u20131458","journal-title":"Life Sci"},{"key":"6_CR26","doi-asserted-by":"crossref","unstructured":"Jordan VC, Gosden B (1983) Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018. Endocrinology 113(2):463\u2013468","DOI":"10.1210\/endo-113-2-463"},{"issue":"1","key":"6_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","volume":"14","author":"TJ Powles","year":"1996","unstructured":"Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S (1996) Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14(1):78\u201384","journal-title":"J Clin Oncol"},{"key":"6_CR28","doi-asserted-by":"crossref","unstructured":"Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC (1991) Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. JNCI J Natl Cancer Inst 83(20):1488\u20131491","DOI":"10.1093\/jnci\/83.20.1488"},{"issue":"9","key":"6_CR29","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJM199608293350907","volume":"335","author":"PG Rose","year":"1996","unstructured":"Rose PG (1996) Endometrial carcinoma. N Engl J Med 335(9):640\u2013649","journal-title":"N Engl J Med"},{"key":"6_CR30","doi-asserted-by":"crossref","unstructured":"Wiklund I, Holst J, Karlberg J, Mattsson L\u00c5, Samsioe G, Sandin K, Von Schoultz B (1992) A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas 14(3):211\u2013224","DOI":"10.1016\/0378-5122(92)90116-L"},{"key":"6_CR31","doi-asserted-by":"crossref","unstructured":"Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Cummings SR (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117(12)\u20131016\u20131037","DOI":"10.7326\/0003-4819-117-12-1016"},{"issue":"14","key":"6_CR32","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1001\/jama.1991.03460140089033","volume":"265","author":"E Barrett-Connor","year":"1991","unstructured":"Barrett-Connor E, Bush TL (1991) Estrogen and coronary heart disease in women. JAMA 265(14):1861\u20131867","journal-title":"JAMA"},{"issue":"4 Suppl","key":"6_CR33","first-page":"18S","volume":"75","author":"RA Lobo","year":"1990","unstructured":"Lobo RA (1990) Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol 75(4 Suppl):18S-25S","journal-title":"Obstet Gynecol"},{"issue":"19","key":"6_CR34","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1056\/NEJM198711053171901","volume":"317","author":"DP Kiel","year":"1987","unstructured":"Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA (1987) Hip fracture and the use of estrogens in postmenopausal women. N Engl J Med 317(19):1169\u20131174","journal-title":"N Engl J Med"},{"key":"6_CR35","doi-asserted-by":"crossref","unstructured":"Miller BA, Feuer EJ, Hankey BF (1993) Recent incidence trends for breast cancer in women and the relevanceof early detection: an update. CA Cancer J Clin 43(1):27\u201341","DOI":"10.3322\/canjclin.43.1.27"},{"issue":"11","key":"6_CR36","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJM199109123251102","volume":"325","author":"MJ Stampfer","year":"1991","unstructured":"Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH (1991) Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses\u2019 Health Study. N Engl J Med 325(11):756\u2013762","journal-title":"N Engl J Med"},{"issue":"11","key":"6_CR37","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1200\/JCO.1993.11.11.2090","volume":"11","author":"PP Rosen","year":"1993","unstructured":"Rosen PP, Groshen S, Kinne D, Norton L (1993) Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0\/T2N0M0 patients with long-term follow-up. J Clin Oncol 11(11):2090\u20132100","journal-title":"J Clin Oncol"},{"issue":"8784","key":"6_CR38","first-page":"1","volume":"339","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1992","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339(8784):1\u201315","journal-title":"Lancet"},{"issue":"6","key":"6_CR39","first-page":"1201","volume":"65","author":"AJ McMichael","year":"1980","unstructured":"McMichael AJ, Potter JD (1980) Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 65(6):1201\u20131207","journal-title":"J Natl Cancer Inst"},{"key":"6_CR40","unstructured":"McMichael AJ, Potter JD (eds) (1985) Host factors in carcinogenesis: certain bile-acid metabolic profiles that selectively increase the risk of proximal colon cancer. J Natl Cancer Inst 75(2):185\u2013191"},{"issue":"4","key":"6_CR41","first-page":"329","volume":"7","author":"E Fernandez","year":"1998","unstructured":"Fernandez E, La Vecchia C, Braga C, Talamini R, Negri E, Parazzini F, Franceschi S (1998) Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol Prev Biomark 7(4):329\u2013333","journal-title":"Cancer Epidemiol Prev Biomark"},{"issue":"17","key":"6_CR42","first-page":"4936","volume":"49","author":"SE Furner","year":"1989","unstructured":"Furner SE, Davis FG, Nelson RL, Haenszel W (1989) A case-control study of large bowel cancer and hormone exposure in women. Can Res 49(17):4936\u20134940","journal-title":"Can Res"},{"key":"6_CR43","doi-asserted-by":"crossref","unstructured":"Calle EE, Miracle-McMahill HL, Thun MJ, Heath Jr CW (1995) Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. JNCI J Natl Cancer Inst 87(7):517\u2013523","DOI":"10.1093\/jnci\/87.7.517"},{"key":"6_CR44","doi-asserted-by":"crossref","unstructured":"Grodstein F, Martinez ME, Platz EA, Giovannucci E, Colditz GA, Kautzky M, Stampfer MJ (1998) Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 128(9):705\u2013712","DOI":"10.7326\/0003-4819-128-9-199805010-00001"},{"key":"6_CR45","doi-asserted-by":"crossref","unstructured":"Reeves GK, Beral V, Green J, Gathani T, Bull D, Million Women Study Collaborators (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7(11):910\u2013918","DOI":"10.1016\/S1470-2045(06)70911-1"},{"key":"6_CR46","doi-asserted-by":"crossref","unstructured":"M\u00f8rch LS, L\u00f8kkegaard E, Andreasen AH, Kr\u00fcger-Kj\u00e6r S, Lidegaard \u00d8 (2009) Hormone therapy and ovarian cancer. Jama 302(3):298\u2013305","DOI":"10.1001\/jama.2009.1052"},{"issue":"10","key":"6_CR47","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1002\/ijc.22790","volume":"121","author":"MA Gates","year":"2007","unstructured":"Gates MA, Tworoger SS, Hecht JL, De Vivo I, Rosner B, Hankinson SE (2007) A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. Int J Cancer 121(10):2225\u20132232","journal-title":"Int J Cancer"},{"key":"6_CR48","doi-asserted-by":"crossref","unstructured":"Green J, Reeves GK, Floud S, Barnes I, Cairns BJ, Gathani T, Beral V (2019) Cohort profile: the million women study. Int J Epidemiol 48(1):28\u201329e","DOI":"10.1093\/ije\/dyy065"}],"container-title":["Cancer Treatment and Research","Therapeutic Approaches in Cancer Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-27156-4_6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T06:02:33Z","timestamp":1686549753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-27156-4_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9783031271557","9783031271564"],"references-count":48,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-27156-4_6","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"13 June 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}